Search
Showing results for "1"
Browse the published work of the Centre's researchers
Research
Prevalence of celiac disease in 52,721 youth with type 1diabetes: International comparison across three continentsTim Jones MBBS DCH FRACP MD Co-head, Diabetes and Obesity Research Co-head, Diabetes and Obesity Research Areas of research expertise: Diabetes
News & Events
Teaching Kitchensthe Teaching Kitchens program will start again on Thursday March 9 from 5-7pm, running for four weeks (every thursday evening).
News & Events
Changes to the continuous glucose monitoring initiative from 1st March, 2022.The Dexcom G6 CGM system will be available through the NDSS to all our patients with Type 1 diabetes.
News & Events
Congratulations VinuthaCongratulations to Dr Vinutha Shetty who has been awarded a Type 1 Diabetes Clinical Research Network’s Mentored Clinician Researcher Fellowship Award for 2017.
News & Events
Preparing for school in 2024It's the new school year and by now your child's school should have a copy of their updated Diabetes Management Plan. Adele Connor, Diabetes in
News & Events
Virtual reality diabetesWhen Josh Wulf’s son was diagnosed with Type 1 Diabetes, little did he know that one day he would be helping other T1D families manage the condition.
Research
Resilience and Diabetes 2 (the RAD2 study)Investigators: Anna Hunt, Ashleigh Lin Stress and anxiety are significant problems in children and adolescence with type 1 diabetes. Not only do
Research
Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBADMitophagy preserves overall mitochondrial fitness by selectively targeting damaged mitochondria for degradation. The regulatory mechanisms that prevent PTEN-induced putative kinase 1 (PINK1) and E3 ubiquitin ligase Parkin (PINK1/Parkin)-dependent mitophagy and other selective autophagy pathways from overreacting while ensuring swift progression once initiated are largely elusive.
Research
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEThe pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.